Journal article
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the breast international group 02-98 phase III trial
C Oakman, PA Francis, J Crown, E Quinaux, M Buyse, E De azambuja, MM vila, M Andersson, B Nordenskjöld, R Jakesz, B Thürlimann, J Gutiérrez, V Harvey, L Punzalan, P Dell'Orto, D Larsimont, I Steinberg, RD Gelber, M Piccart-Gebhart, G Viale Show all
Annals of Oncology | Published : 2013
Abstract
Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. Methods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m. 2) × 4 → classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600..
View full abstractGrants
Awarded by Sanofi
Funding Acknowledgements
This work was sponsored and funded by sanofi-aventis. Transtax analyses were funded by Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy. Funding was also provided by the National Health and Medical Research Council [grant numbers 100925, 351164] to the Australian New Zealand Breast Cancer Trials Group.r Employment is disclosed by IS [Sanofi pharmaceuticals (AVP global medical leader)]. Stock ownership is disclosed by IS (Sanofi pharmaceuticals). Consultancy is disclosed by ADL (Sanofi), BT (Sanofi), JG (Roche, Bristol Myer Squibb) and MP-G (Sanofi, Amgen, Bayer, Bristol Myer Squibb, Roche, Glaxosmithkline, Boehringer Inghelneim, PharmaMar). Honoraria is disclosed by ADL (Sanofi), BT (Sanofi), JC (Sanofi, Roche Genentech), JG (Novartis, Roche, BMS), PAF (Sanofi), MP-G (Sanofi, Amgen, Bayer, Bristol Myer Squibb, Roche, Glaxosmithkline, Boehringer, PharmaMar) and VH (Roche, Sanofi). Research funding is disclosed by BT (Sanofi), JC (Sanofi, Roche Genentech), MP-G (Sanofi, Amgen, Bayer, Bristol Myer Squibb, Roche, Glaxosmithkline, Boehringer Inghelneim, PharmaMar) and VH (Roche). Other remuneration, including travel grants, is dislcosed by BT (Sanofi), JG (Roche, Novartis) and PAF (Sanofi). All the remaining authors have declared no conflicts of interest.